• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

Provectus Pharmaceuticals Adds Second Center to Phase 2 Clinical Trial of PV-10

Posted on: Tuesday, 18 December 2007, 12:00 CST

Provectus Pharmaceuticals, Inc. (OTCBB: PVCT, http://www.pvct.com) has begun recruitment for its Phase 2 clinical trial of the Company's lead oncology agent PV-10 (also known as Provecta) at a second major center, now covering Brisbane, Australia in addition to Sydney, Australia. Over the next several months, the Company expects to continue expansion of the study to include sites in most major population centers in Australia as well as several sites in the United States.

Phase 2 clinical testing of PV-10 is designed to assess the agent as a treatment for Stage III and IV metastatic melanoma, the most aggressive and deadly form of skin cancer. The multi-center study will evaluate efficacy of PV-10 in a total of 80 subjects.

In the study, PV-10 is being injected into up to 20 tumors in each subject. Additional treatment with PV-10 may be made 8 to 16 weeks after this initial injection, if deemed necessary by the investigator. Response will be observed for one (1) year, allowing data to be gathered for assessment of objective response rate, progression free survival, quality of life and safety. An interim assessment of safety and efficacy will be conducted after treatment of the first 20 and first 40 subjects. Details of the study are available at the www.ClincalTrials.gov clinical trials registry.

"Opening the center at Brisbane is the start of our expansion of our Phase 2 studies in melanoma to multiple sites including the U.S.," said Craig Dees, Ph.D., CEO of Provectus. "It is the first step in our effort to get the treatment available to as many patients as possible in the shortest possible time."

In Phase 1 testing, in more than 100 metastatic melanoma tumors in 20 subjects, PV-10, which has received orphan drug designation in the U.S., was well tolerated with generally mild side effects. Dr. Dees noted, "The 40% objective response rate and 75% rate of disease control observed in the initial study bode well for success in licensure of PV-10 for treatment of this most challenging of cancers."

About Provectus

Provectus Pharmaceuticals specializes in developing oncology and dermatology therapies that are safer, more effective, and less invasive than conventional therapies. Provectus is currently conducting Phase 2 clinical trials of their proprietary drugs PV-10 as a therapy for melanoma and breast cancer, and PH-10 as a topical treatment for moderate to severe psoriasis. The Company has received orphan drug designation from the FDA for metastatic melanoma. For additional information about Provectus please visit the Company's website at www.pvct.com or contact the Investor Relations Group via the information provided below.

FORWARD-LOOKING STATEMENTS

The forward-looking statements contained herein are subject to certain risks and uncertainties that could cause actual results to differ materially from those reflected in the forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which reflect management's analysis only as of the date hereof. The company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date thereof.

Source: Business Wire

More News in this Category